Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4537

1.

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation.

Steinberg BA, Greiner MA, Hammill BG, Curtis LH, Benjamin EJ, Heckbert SR, Piccini JP.

Cardiovasc Ther. 2015 Apr 30. doi: 10.1111/1755-5922.12129. [Epub ahead of print]

PMID:
25930214
2.

Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.

Larsen TB, Potpara T, Dagres N, Proclemer A, Sciarrafia E, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association; Scientific Initiative Committee European Heart Rhythm Association.

Europace. 2015 May;17(5):819-24. doi: 10.1093/europace/euv116.

PMID:
25926476
3.

Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in taiwan: a nationwide cohort study.

Chen PC, Lip GY, Yeh G, Lin HJ, Chien KL.

PLoS One. 2015 Apr 29;10(4):e0125257. doi: 10.1371/journal.pone.0125257. eCollection 2015.

4.

Preoperative warfarin reversal for early hip fracture surgery.

Moores TS, Beaven A, Cattell AE, Baker C, Roberts PJ.

J Orthop Surg (Hong Kong). 2015 Apr;23(1):33-6.

5.

Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation.

Hao L, Zhong JQ, Zhang W, Rong B, Xie F, Wang JT, Yue X, Zheng ZT, Zhu Q, Zhang Y.

Int J Cardiol. 2015 Apr 16;190:63-66. doi: 10.1016/j.ijcard.2015.04.104. [Epub ahead of print] No abstract available.

PMID:
25912125
6.

Analgesic use before and after oral anticoagulant initiation-a population-based study in Finland.

Ilomäki J, Helin-Salmivaara A, Huupponen R, Rikala M, Kirkpatrick CM, Korhonen MJ.

Eur J Clin Pharmacol. 2015 Apr 26. [Epub ahead of print]

PMID:
25911438
7.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

8.

Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials.

Renda G, di Nicola M, De Caterina R.

Am J Med. 2015 Apr 21. pii: S0002-9343(15)00356-3. doi: 10.1016/j.amjmed.2015.03.034. [Epub ahead of print]

PMID:
25910790
9.

[Management of new oral anticoagulants in gastrointestinal bleeding and endoscopy].

Del Molino F, Gonzalez I, Saperas E.

Gastroenterol Hepatol. 2015 Apr 20. pii: S0210-5705(15)00093-X. doi: 10.1016/j.gastrohep.2015.02.014. [Epub ahead of print] Spanish.

PMID:
25908223
10.

When Is a Double Better Than a TRIPLE?: Stenting in Patients With Atrial Fibrillation.

Bhatt DL.

J Am Coll Cardiol. 2015 Apr 28;65(16):1630-2. doi: 10.1016/j.jacc.2015.02.051. No abstract available.

PMID:
25908067
11.

Amiodarone Induced Thyrotoxicosis.

Macchia PE.

In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2012 Jul 21.

12.

Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation.

Phan K, Wang N, Pison L, Kumar N, Hitos K, Thomas SP.

Int J Cardiol. 2015 Apr 11;189:199-203. doi: 10.1016/j.ijcard.2015.04.072. [Epub ahead of print] No abstract available.

PMID:
25897906
13.

Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.

Hsu JC, Hsieh CY, Yang YH, Lu CY.

PLoS One. 2015 Apr 21;10(4):e0124806. doi: 10.1371/journal.pone.0124806. eCollection 2015.

14.

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.

Abe J, Umetsu R, Kato Y, Ueda N, Nakayama Y, Suzuki Y, Suzuki T, Nagasawa H, Kinosada Y, Nakamura M.

Int J Med Sci. 2015 Mar 28;12(4):312-21. doi: 10.7150/ijms.10703. eCollection 2015.

15.

To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.

Granziera S, Bertozzo G, Pengo V, Marigo L, Denas G, Petruzzellis F, Rossi K, Infante T, Padayattil SJ, Perissinotto E, Manzato E, Nante G.

Intern Emerg Med. 2015 Apr 21. [Epub ahead of print]

PMID:
25896181
16.

Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation.

Bhagirath V, Bosch J, Eikelboom J.

Ann Intern Med. 2015 Apr 21;162(8):JC4. doi: 10.7326/ACPJC-2015-162-8-004. No abstract available.

PMID:
25894049
17.

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Apr;32(4):387. doi: 10.1007/s12325-015-0202-8. No abstract available.

PMID:
25893513
18.

Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention.

Savoia C, Sada L, Volpe M.

Curr Hypertens Rep. 2015 Jun;17(6):553. doi: 10.1007/s11906-015-0553-1.

PMID:
25893476
19.

Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.

Rong F, Jia B, Huang P, Lynn HS, Zhang W.

Thromb Res. 2015 Apr 11. pii: S0049-3848(15)00159-0. doi: 10.1016/j.thromres.2015.04.004. [Epub ahead of print]

PMID:
25891842
20.

Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study.

Suzuki M, Fukamizu S, Oyama JI, Mizukami A, Matsumura A, Hashimoto Y, Node K.

Int J Cardiol. 2015 Apr 7;188:52-53. doi: 10.1016/j.ijcard.2015.04.037. [Epub ahead of print] No abstract available.

PMID:
25889327
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk